Core Insights - MCAP Inc. reported a fourth quarter 2025 earnings per share (EPS) of $0.13, reflecting a 40% quarter-over-quarter increase, with quarterly EBITDA of $4.7 million and a full year EBITDA of $21 million [1]. Group 1: Financial Performance - The company achieved a quarterly EBITDA of $4.7 million for Q4 2025 [1]. - Full year EBITDA for 2025 was reported at $21 million [1]. - The EPS of $0.13 represents a significant increase of 40% compared to the previous quarter [1]. Group 2: Business Strategy - MCAP is focused on expanding its business through investments in customer relationships, application software development, and securities execution platforms [2]. - The company is actively seeking additional mergers and acquisitions (M&A) opportunities that align with its core competencies to enhance long-term shareholder value [2]. Group 3: Company Overview - MCAP Inc. is a U.S.-based public holding company with subsidiaries and investments in various companies, primarily in the financial technology sector [3]. - The company's main focus is on electronic market making, execution sector, securities trading technologies, and alternative trading platforms [3].

Core Insights - S&P Global, in collaboration with Cambridge Associates and Mercer, has launched the Private Markets Performance Analytics datasets aimed at providing standardized data for private credit and real assets, enhancing investors' ability to compare performance and manage risk [1][3]. Group 1: Dataset Features - The datasets are powered by S&P Global's iLEVEL portfolio monitoring platform and utilize a proprietary private markets taxonomy to standardize, aggregate, and anonymize data [2]. - The initial release includes comprehensive data across thousands of funds and their underlying assets, with future datasets for private equity and other asset classes expected later in 2026 [1][4]. Group 2: Investor Benefits - Investors can leverage these datasets to compare performance across similar investments using consistent metrics, manage risk through detailed market and deal-level data, and assess portfolio impacts from market events with increased speed and confidence [5]. - The datasets support various use cases, including portfolio performance monitoring, risk management, asset allocation decisions, fundraising analysis, and competitive insights, benefiting investment teams, risk managers, and senior leadership at both LP and GP organizations [4][5]. Group 3: Industry Context - The collaboration addresses the growing need for consistent, decision-ready intelligence in the evolving private markets landscape, transforming fragmented information into actionable insights for investors [3][4]. - As the number of managers in private markets increases, access to comprehensive performance data becomes crucial for making informed investment decisions [4].

Core Insights - Jones Soda Co. reported a significant increase in revenue for Q4 2025, with a 450% rise to $11.7 million and a positive adjusted EBITDA of $0.5 million [1][3] - For the full year 2025, revenue increased by 42% to $25.3 million, with an adjusted EBITDA improvement of $5.2 million year-over-year [1][5] Financial Performance - Revenue from continuing operations rose by 42% to $25.3 million compared to $17.8 million in 2024, driven by new core soda sales and increased direct-to-consumer sales [3][5] - Adjusted gross profit margin from continuing operations increased to 32%, up from 27% in the previous year [3][6] - The net loss from continuing operations was reduced by 82% to $1.8 million, or $(0.01) per share, compared to a net loss of $9.9 million, or $(0.09) per share in 2024 [3][8] - Total operating expenses from continuing operations were $4.1 million, up from $3.2 million, primarily due to license and broker fees related to revenue growth [3][6] Business Highlights - The company launched new products, including Supply Pack and Rocket Bottle, in partnership with a leading gaming franchise [3][4] - Expanded distribution with a major warehouse club operator, significantly increasing product availability across Canada [3][4] - The company anticipates Q1 2026 revenue to exceed $12 million, representing a 260% increase year-over-year, and expects FY2026 revenue to exceed $40 million, up over 60% [2][11] Operational Improvements - The CEO highlighted that 2025 was a transformational year, marked by strong growth, expanded distribution, and operational improvements [4] - The company focused on streamlining operations, optimizing the supply chain, and implementing cost management strategies [4] Cash Position - As of December 31, 2025, the company had cash and cash equivalents of $3.6 million, up from $1.3 million at the end of 2024 [9]

Core Insights - Tvardi Therapeutics is advancing its clinical pipeline with two significant milestones expected in 2026: topline data from a healthy volunteer study of TTI-109 in Q2 and topline data from a Phase 2 trial of TTI-101 in hepatocellular carcinoma (HCC) in H2 [1][3] Financial Performance - Research and development expenses for Q4 2025 were $5.5 million, down from $8.6 million in Q4 2024, while total R&D expenses for the full year 2025 were $18.0 million compared to $23.7 million in 2024, primarily due to reduced clinical costs for TTI-101 [4] - General and administrative expenses for Q4 2025 were $2.1 million, slightly down from $2.2 million in Q4 2024, but increased for the full year to $8.7 million from $4.5 million in 2024, mainly due to higher professional fees related to the merger with Cara Therapeutics [7] - The net loss for Q4 2025 was $7.3 million, an improvement from a net loss of $12.7 million in Q4 2024, with a full-year net loss of $18.2 million compared to $29.4 million in 2024 [8][9] Cash Position - As of December 31, 2025, cash, cash equivalents, and short-term investments totaled $30.8 million, slightly down from $31.6 million in 2024, with the company expecting this cash runway to fund operations through Q4 2026 [10] Clinical Development Updates - The ongoing Phase 2 REVERT LIVER CANCER trial is expected to report topline results in the second half of 2026, allowing for additional data maturation and insights [5][6] - Preliminary data from the Phase 2 IPF trial of TTI-101 showed a 9.4% reduction in fibrosis score compared to 2.4% for placebo, indicating promising efficacy [5]

Core Insights - BrainStorm Cell Therapeutics Inc. reported its financial results for the full year 2025 and highlighted advancements in its clinical programs, particularly for NurOwn, a treatment for ALS [1][2]. Financial Performance - For the year ended December 31, 2025, the company reported a net loss of approximately $10.3 million, an improvement from a net loss of about $11.6 million in 2024 [9][17]. - Research and development expenditures for 2025 were $4.2 million, down from $4.7 million in 2024 [9][17]. - General and administrative expenses decreased to approximately $5.8 million in 2025 from $7.0 million in 2024 [9][17]. - Cash and cash equivalents were approximately $0.3 million as of December 31, 2025, with an additional $2 million secured through private placements in early 2026 [9][3]. Clinical Development - The company is advancing NurOwn into a Phase 3b confirmatory study, having received FDA clearance in 2025 [2]. - The Phase 3b ENDURANCE study is expected to enroll around 200 participants and will consist of a 24-week randomized, double-blind, placebo-controlled portion followed by a 24-week open-label extension [2][4]. - The primary efficacy endpoint for the trial will be the change from baseline to Week 24 on the ALSFRS-R scale [2]. Expanded Access Program (EAP) Results - In the EAP, 50% of patients (5 out of 10) remained alive, with an estimated mean survival of approximately 84 months [4]. - All 10 EAP patients exceeded a 5-year survival rate compared to the historical rate of about 20% [4]. Strategic Financing - The company secured $2 million in strategic financing through two private placement agreements in February 2026, aimed at supporting operational objectives and the Phase 3b trial preparations [3][9]. Technology Overview - NurOwn technology utilizes autologous MSC-NTF cells derived from bone marrow to deliver neurotrophic factors, targeting neurodegenerative diseases [5][6]. - The platform has received Orphan Drug designation from both the FDA and EMA for ALS treatment [7].

Core Viewpoint - Bank OZK is set to report its first quarter 2026 earnings on April 21, 2026, after market close, with management comments released simultaneously [1] Group 1: Earnings Announcement - The earnings report for the first quarter of 2026 will be available on the Bank's investor relations website [1] - A conference call for questions will be held on April 22, 2026, at 7:30 a.m. CT (8:30 a.m. ET) [2] - Participants can access the conference call via webcast or telephone, with registration required for telephone access [2] Group 2: Company Overview - Bank OZK, established in 1903, operates 268 offices across nine states, including Arkansas, Georgia, Florida, Texas, North Carolina, Tennessee, New York, California, and Mississippi [3] - As of December 31, 2025, the Bank had total assets of $40.8 billion [3]

Core Viewpoint - T1 Energy Inc. reported Q4 2025 results with record module production but faced a significant net loss due to heavy investments in scaling operations, leading to investor disappointment despite ongoing progress on the G2_Austin solar cell project [3][4][7]. Financial Performance - T1 Energy achieved record quarterly module production of 1.13 GW, generating $358.6 million in revenue, which was below analyst expectations of $368.2 million [3][4][7]. - The company reported a GAAP net loss of $190 million, translating to an EPS of -$0.87, which was a significant improvement from -$2.59 per share in Q4 2024 [3][7]. - The loss from continuing operations was approximately $153 million, with an EPS of -$0.70 [7]. G2_Austin Solar Cell Project - The G2_Austin project is progressing well, with construction on the first 2.1 GW phase underway and on schedule for commercial production by late 2026 [4][6]. - The project is expected to create up to 1,800 jobs and significantly increase U.S. solar cell manufacturing capacity, exceeding current total U.S. silicon-based cell capacity [4]. - T1 Energy is targeting financial close for the remaining ~$350 million of funding in April 2026 and has optimized project costs through efficient capital use [5][7]. Strategic Partnerships and Growth - The company has partnered with Yates Construction for the G2_Austin project and is collaborating with technology and supply chain partners to enhance project execution [5]. - T1 Energy is in a growth phase, focusing on rapid revenue scaling from its G1_Dallas factory and major capacity expansion via G2_Austin, with expectations of improved margins and profitability in 2027 and beyond [6].

Core Insights - The S&P 500 ETF experienced a decline of over 5% in March due to the impact of the war in Iran, which caused a significant increase in oil prices [1] Group 1: Market Performance - The S&P 500 ETF (SP500, SPY) fell more than 5% during March [1] Group 2: Geopolitical Impact - The war in Iran led to soaring oil prices, contributing to the decline in stock prices [1] - Despite the downturn, there were emerging geopolitical rays of hope towards the end of the quarter [1]

Company announcement – No. 6 / 2026 Total number of shares and voting rights in Zealand Pharma as of March 31, 2026 Copenhagen, Denmark, March 31, 2026 – Zealand Pharma A/S (“Zealand Pharma” or "the Company")  (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today announces, in accordance with section 32 of the Danish Capital Markets Act, the total number of shares and voting rights in the Company at the end of a calendar month during which changes to i ...

Core Viewpoint - Gunnison Copper Corp. has filed an updated Preliminary Economic Assessment (PEA) for its Gunnison Copper Project, indicating strong economic viability and significant contributions to the U.S. copper supply [1][2]. Economic Assessment - The PEA outlines a large-scale copper project with an after-tax NPV8 of approximately US$2.0 billion, an internal rate of return of 22.5%, and a payback period of 3.9 years at a base case copper price of $4.60/lb [2][4]. - Under a higher copper price scenario of $5.75/lb, the after-tax NPV8 increases to approximately US$3.2 billion, with an internal rate of return of 31.8% and a payback period of 2.6 years [4]. Project Metrics - The project has a construction period of 24 months and a life of mine of 21 years, with a total of 641 million tons of mineralized material expected to be mined [6][7]. - The average annual copper production is projected to be 174 million pounds for the first 15 years, contributing significantly to U.S. refined copper production [7]. Economic Impact - The project is expected to create over 112,744 job years and generate $558 million in state and local taxes, $1.43 billion in federal taxes, and $21.9 billion in total economic output [4][5]. Financial Metrics - Key financial metrics at a $4.60/lb copper price include an average annual free cash flow of $366 million over the first 15 years and an EBITDA of $486 million [5][6]. - The cash cost is estimated at $1.70 per pound of copper, with sustaining cash costs of $2.00 and all-in sustaining costs of $2.05 per pound, positioning the project in the lower half of the global cost curve for copper mining [7]. Mineral Resource Estimate - The Gunnison Deposit's mineral resources are classified into Measured, Indicated, and Inferred categories, with a total of 846.1 million short tons at an average grade of 0.33% copper [10][12]. - The project has a significant amount of inferred resources, which are considered too speculative to be categorized as mineral reserves [4][9].